| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $188,883,851 ) (Continued on the next page) |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Developing Automated tools for Cervical Cancer Radiotherapy Treatment for Zambian Women living with HIV (Biospecimen/Cohort) | 006 | 48 | NIH | 9/3/2024 | $67,499 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Developing Automated tools for Cervical Cancer Radiotherapy Treatment for Zambian Women living with HIV (Biospecimen/Cohort) | 005 | 48 | NIH | 7/29/2024 | $11,270,944 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Developing Automated tools for Cervical Cancer Radiotherapy Treatment for Zambian Women living with HIV (Biospecimen/Cohort) | 010 | 48 | NIH | 9/13/2024 | $0 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Developing Automated tools for Cervical Cancer Radiotherapy Treatment for Zambian Women living with HIV (Biospecimen/Cohort) | 009 | 48 | NIH | 9/12/2024 | $204,375 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25CA265800 | Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) program | 000 | 2 | NIH | 7/31/2024 | $323,302 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA272565 | Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | 001 | 2 | NIH | 6/7/2024 | $117,865 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA272945 | Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer | 000 | 3 | NIH | 6/6/2024 | $510,751 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273984 | Hypoglossal neuropathy in the pathogenesis of radiation associated dysphagia (hRAD) | 000 | 2 | NIH | 4/22/2024 | $196,648 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA248731 | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | 001 | 4 | NIH | 4/17/2024 | $28,033 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA234183 | Therapeutic strategies against EGFR exon 20 mutant lung cancer | 001 | 5 | NIH | 4/17/2024 | $27,873 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 3 | NIH | 3/4/2024 | $260,582 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA272565 | Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | 000 | 2 | NIH | 5/6/2024 | $489,614 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA234183 | Therapeutic strategies against EGFR exon 20 mutant lung cancer | 000 | 5 | NIH | 11/15/2023 | $501,734 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA248731 | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | 000 | 4 | NIH | 1/17/2024 | $504,576 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 001 | 3 | NIH | 9/9/2024 | $41,519 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258100 | Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer | 000 | 4 | NIH | 4/18/2024 | $352,047 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 000 | 3 | NIH | 3/19/2024 | $533,810 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 001 | 2 | NIH | 11/16/2023 | $57,406 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 002 | 2 | NIH | 2/19/2024 | $0 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 000 | 2 | NIH | 11/15/2023 | $170,405 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 001 | 2 | NIH | 2/2/2024 | $0 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 2 | NIH | 1/17/2024 | $500,835 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255021 | A pro-metastatic secretory pathway activated by p53 loss in lung cancer | 000 | 4 | NIH | 7/1/2024 | $530,294 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U24CA274212 | Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions | 000 | 3 | NIH | 8/13/2024 | $367,661 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA239921 | A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical Cancer Risk Reduction in HIV+ Women living in Mozambique | 000 | 4 | NIH | 8/2/2024 | $736,499 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21NS130323 | Elucidating the Role of the Gut and Tumor Microbiome in Malignant Glioma | 000 | 2 | NIH | 5/10/2024 | $202,500 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 002 | 2 | NIH | 5/13/2024 | $44,519 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 004 | 2 | NIH | 4/30/2024 | $3,190 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 003 | 2 | NIH | 4/17/2024 | $9,465 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA264583 | Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development | 001 | 3 | NIH | 7/8/2024 | $411,223 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255721 | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | 001 | 4 | NIH | 4/17/2024 | $24,846 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P01AI139449 | Mechanisms controlling distinct growth and functional characteristics of the perinatal and adult thymus | 000 | 5 | NIH | 8/16/2024 | $2,288,223 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 001 | 2 | NIH | 4/17/2024 | $24,007 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273656 | Boosting anti-tumor immunity in the omentum for metastasis prevention | 000 | 2 | NIH | 4/15/2024 | $215,846 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 001 | 4 | NIH | 4/16/2024 | $17,194 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 1 | NIH | 3/4/2024 | $672,300 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 002 | 2 | NIH | 8/14/2024 | $0 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA009599 | Training of Academic Surgical Oncologists | 002 | 36 | NIH | 6/28/2024 | $562,040 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255074 | Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors | 000 | 4 | NIH | 8/9/2024 | $352,047 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 001 | 2 | NIH | 6/14/2024 | $56,146 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F32CA271697 | Targeting Quiescence Pathways to Overcome Chemoresistance in EVI1-Overexpressing Leukemia | 000 | 3 | NIH | 6/26/2024 | $81,592 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA231522 | Dyadic yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers | 000 | 7 | NIH | 8/14/2024 | $365,817 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35CA263815 | Biology and Function of Exosomes in Cancer | 000 | 3 | NIH | 8/6/2024 | $914,441 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 000 | 2 | NIH | 1/4/2024 | $631,655 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 4 | NIH | 2/9/2024 | $309,484 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 000 | 2 | NIH | 11/29/2023 | $452,669 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U54CA274371 | Effects of Tissue Block Age on Reliability and Accuracy of In situ Transcriptomics Across Organ Sites using Xenium Technology | 004 | 3 | NIH | 9/10/2024 | $199,862 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 001 | 2 | NIH | 4/17/2024 | $25,149 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA289456 | Targeting the gut microbiome to inhibit melanoma lymph node metastases | 000 | 1 | NIH | 4/26/2024 | $530,612 |
|
